Sentence examples for dose of alogliptin from inspiring English sources
These events occurred primarily at the highest dose of alogliptin.
54, 55 Mean plasma DPP-4 inhibition after a single dose of alogliptin (25 mg to 800 mg) ranged from 74.3%to94%4% at 24 hours and 47.5% to 83% at 72 hours.
Furthermore, the effect of either dose of alogliptin (12.5 mg and 25 mg) on serum lev of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides was not also significantly different from controls (Table 3).
The pooled SMD in alogliptin 12.5 mg treated vs controls and alogliptin 25 mg treated vs controls also showed a statistically significant reduction in FPG level among patients treated with either dose of alogliptin (SMD = −0.43, 95% CI = −0.6 to −0.26; SMD = −0.51, 95% CI = −0.68 to −0.34 for alogliptin 12.5 mg and alogliptin 25 mg, respectively).
Reductions in fasting plasma glucose were observed at all metformin doses and were significant in patients receiving either dose of alogliptin compared with placebo: 0 mg/dL, −19 mg/dL and −17 mg/dL with placebo, alogliptin 12.5 mg and 25 mg respectively.
Moreover, addition of either dose of alogliptin to a previously prescribed antidiabetic drug(s), in patients with inadequately controlled type 2 diabetes, has shown a statistically significant reduction in HbA1c and FPG - better than the previously prescribed antidiabetic drug(s) alone.
Covington et al studied single increasing doses of alogliptin in 36 subjects.
The doses of alogliptin were used as described previously [ 7, 8].
54 DPP-4 enzyme activity and active GLP-1 levels were measured in human studies after single and multiple doses of alogliptin.
The effectiveness and tolerability of the two doses of alogliptin (12.5 mg and 25 mg) alone and as an added-on with other antidiabetic drug as compared to placebo or other antidiabetic drug were determined using the random effects model.
The number of patients who discontinued their medication due to adverse events while receiving either doses of alogliptin was not different from the number patients who were receiving placebo or other antidiabetic drugs.
